Ollie’s Bargain Outlet (NASDAQ:OLLI) had its price objective increased by JPMorgan Chase & Co. from $70.00 to $84.00 in a report released on Tuesday morning. They currently have an overweight rating on the stock.
Several other equities analysts have also recently issued reports
In my whole life, I have known no wise people (over a broad subject matter area) who didn’t read all the time – none, zero. Youd be amazed at how much Warren reads – and at how much I read. My children laugh at me. They think Im a book with a couple of legs sticking out.
– Charlie Munger
Nektar Therapeutics (NASDAQ:NKTR) is one of the most robust growers....More>>>
Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical....More>>>
Engineers Gate Manager LP purchased a new stake in shares of Tutor Perini (NYSE:TPC) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 27,812 shares of the construction company’s stock, valued at approxim
News articles about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of
The Geron (GERN) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing.
AXIS Capital (NYSE: AXS) and Kingstone Companies (NASDAQ:KINS) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.